Previous close | 47.49 |
Open | 48.46 |
Bid | 47.38 x 200 |
Ask | 47.52 x 200 |
Day's range | 47.22 - 48.76 |
52-week range | 19.83 - 94.75 |
Volume | |
Avg. volume | 1,421,929 |
Market cap | 5.757B |
Beta (5Y monthly) | 0.89 |
PE ratio (TTM) | N/A |
EPS (TTM) | -4.45 |
Earnings date | 07 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 81.73 |
Syros Pharmaceuticals (SYRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
WALTHAM, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that 14 abstracts, 11 of which are oral presentations, will be presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting to be held May 5 - 9 in Seattle. The data continue to reinforce the robust efficacy and safety profile of SYFOVRE® (pegcetacoplan injection) for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). “The 11 oral
Apellis Pharmaceuticals (APLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.